ClinicalTrials.gg
WithdrawnNCT02212613Updated Jul 7, 2016

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

A Phase 3 interventional study of Brexpiprazole in Major Depressive Disorder and Irritability, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-07-07.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
23rd of 24
0 · median 189
Started
2014
with 1 other
Phase 3
16 of 24
none open now
Registered
16th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 23rd largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 16th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability

03

Conditions studied

  • Major Depressive Disorder and Irritability

Keywords

  • Major Depressive Disorder
  • Mental Disorders, nonpsychotic episode, antipsychotic
  • Mood Disorder, psychotic disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 to 55 years of age, inclusive, at the time of with a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the , Fourth Edition, Text Revision (DSM-IV-TR™) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation

    • Have received a single, trial-approved SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening
    • Have a treatment history of inadequate ADT response to at least one ADT (but not > 3) for the current episode. The current major depressive episode must be ≥ 6 weeks in duration. (An inadequate ADT response is defined as \< 50% reduction in depressive symptom severity, as measured by subject self-report on the MGH-ATRQ.)
    • To be eligible for this trial

      • Have a MADRS Total Score of 20 or more at screening and the Phase A baseline, and have a MADRS Total Score of 18 or more at the Phase B baseline
      • Have no more than 20% improvement in MADRS Total Score at Phase B baseline compared to Phase A baseline
      • Have a score of 6 or more on the KSQ based on the Well being and Reversal Distress Anger-hostility subscales at screening, Phase A baseline, and Phase B baseline
      • Have anger attacks as documented by the AAQ at screening, Phase A baseline, and Phase B baseline
    • Are right-handed (defined according to the Edinburgh Handedness Inventory) and have normal hearing and normal/corrected-to-normal vision
    • Are willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period
    • Eligibility confirmed through a telephone SAFER interview with the subject and an independent expert centralized rater

Exclusion criteria

  • Have a current need for involuntary commitment or have been hospitalized within 4 weeks of screening for the current major depressive episode

    • Have a current Axis I diagnosis of any of the following: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified; eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; or post-traumatic stress disorder
    • Have any of the following current Axis II DSM-IV-TR diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation
    • Experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally

    Drug: Brexpiprazole

Interventions

  • Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally

    Also known as: OPC-34712

06

What researchers measure

Primary outcomes

  1. Change from Phase B baseline to Phase B Week 6 in functional magnetic resonance imaging (fMRI) BOLD activation score in the ventromedial prefrontal cortex and amygdala, scanned by fMRI during performance of the Emotion-induction Task

    Time frame: Week 6

Secondary outcomes

  1. Change from Phase B baseline to Phase B Week 6 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score

    Time frame: Week 6

  2. Change from Phase B baseline to Phase B Week 6 in Spielberger State Trait Anger Expression Inventory (STAXI-2) Part 1

    Time frame: Week 6

  3. Change from Phase B baseline to Phase B Week 6 in Visual Analog Scale (VAS)

    Time frame: Week 6

  4. Change from Phase B baseline to Phase B Week 6 in Clinical Global Impression - Severity of Illness Scale (CGI-S) score

    Time frame: Week 6

  5. Clinical Global Impression - Improvement Scale (CGI-I) score at Phase B Week 6

    Time frame: Week 6

  6. MADRS response rate, where response is defined as ≥ 50% reduction in respective total scores from Phase B baseline to Phase B Week 6

    Time frame: Week 6

  7. MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Phase B baseline to Phase B Week 6

    Time frame: Week 6

  8. Change from Phase B baseline to Phase B Week 6 in Sheehan Disability Scale (SDS) 3-item mean score

    Time frame: Week 6

  9. Change from Phase B baseline to Phase B Week 6 in Anger Attacks Questionnaire (AAQ) score

    Time frame: Week 6

  10. Change from Phase B baseline to Phase B Week 6 in Symptoms of Depression Questionnaire (SDQ)

    Time frame: Week 6

  11. Change from Phase B baseline to Phase B Week 6 in Kellner Symptom Questionnaire (KSQ)

    Time frame: Week 6

  12. Change from Phase B baseline to Phase B Week 6 in Barratt Impulsiveness Scale 11 item (BIS-11) Total Score

    Time frame: Week 6

07

Study locations

1 site
  • Emory University
    Atlanta, Georgia 30329, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2014
First posted
Aug 8, 2014
Start
Sep 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Jul 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02212613
Responsible party
Sponsor
First posted
Aug 8, 2014
Start date
Sep 2014
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Jul 7, 2016

Study contacts

Junichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion